Cardioprotection and ACE inhibitors

S G Ball1

  • 1Dept. of Cardiovascular Studies, University of Leeds, England.

Clinical Physiology and Biochemistry
|January 1, 1992
PubMed

Insights

Angiotensin converting enzyme (ACE) inhibitors effectively lower blood pressure and manage heart failure. Ongoing trials are investigating their impact on reducing myocardial infarction consequences and prolonging life in heart failure patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Angiotensin converting enzyme (ACE) inhibitors are established treatments for hypertension and heart failure.
  • Their efficacy in blood pressure reduction is comparable to other antihypertensive agents.
  • Combined with diuretics, ACE inhibitors show potential to revolutionize chronic heart failure management.

Purpose of the Study:

  • To evaluate the effectiveness of ACE inhibitors in reducing myocardial infarction rates and their consequences.
  • To determine if ACE inhibitors prolong survival in patients with chronic heart failure and post-myocardial infarction.

Main Methods:

  • Review of current clinical practices and ongoing major clinical trials (e.g., V-HeFT II, SOLVD, CONSENSUS II, SAVE, AIRE, GISSI III, ISIS IV).
  • Analysis of pharmacological profiles of available ACE inhibitors.

Main Results:

  • ACE inhibitors are effective in lowering blood pressure and managing chronic heart failure symptoms.
  • Evidence is accumulating on their potential to reduce mortality in heart failure and post-myocardial infarction settings.

Conclusions:

  • ACE inhibitors are valuable tools in managing hypertension and heart failure.
  • Further results from ongoing trials are anticipated to clarify their role in reducing cardiovascular mortality.
  • Physicians can select from various ACE inhibitors with distinct pharmacological profiles.

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...